No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Compounding Pharmacies Push Back on Novo Nordisk’s FDA Petition
In October 2024, we reported that Novo Nordisk requested the US FDA to include semaglutide in the FDA’s Demonstrable Difficulties for Compounding (DDC) list, citing safety concerns. In a response made available on 26 November 2024, the US Alliance for Pharmacy...